Plasma haemostatic and fibrinolytic activities and their relationship to levels of serum lipids and apolipoproteins in endogenous hypertriglyceridemic patients

Journal of Sichuan University (Medical Science)

Volumn 34, Issue 3, 2003, Pages 405-408

  Shen, Tao ^a   Bai, Huai ^a   Liu, Bingwen ^a   Liu, Yu ^a   Zhang, Zuhui ^a   Deng, Zuyue ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Apolipoproteins; Blood glucose; Blood lipids; Coagulating activity; Fibrinolytic activity; Hypertriglyceridemia

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN C; APOLIPOPROTEIN E; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0141959101     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Austin MA, Hoknson JE, Edwards KL. Hypertriglyceridemia as a Cardiovascular Risk Factor. Am J Cardiol, 1998; 81 (4A): 7B
2. Simpson HCR, Mann JI, Meade TW, et al. Hypertriglyceridemia and hypercoagulability. The Lancet, 1983; 1(8327): 786
3. Moyer MP, Tracy RP, Tracy PB, et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Bio, 1998; 18(3): 458
4. Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arteriosclerosis and Thrombosis, 1992; 12(1): 19
5. Li XN, Grenett HE, Demissie RLBS, et al. Genotype-Specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp (a) in cultured human endothelial cells. Arterioscler Thromb Vasc Bio, 1997; 17 (11): 3215
6. Eriksson P, Nilsson L, Karpe F, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Bio, 1998; 18(1): 20
7. Chan P, Huang T-Y, Shich S, et al. Trombophilia in patients with hypertriglyceridemia. J Thrombosis and Thrombolysis, 1997; 4: 425
8. Griffin JH, Kojima K, Banka CL, et al. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest, 1999; 103 (2): 219
9. Nofer JR, Walter M, Kehrel B, et al. HDL3-Mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1, 2-diacylglycerol and inositol 1, 4, 5-tri-phosphate. Arterioscler Thromb Vasc Bio, 1998; 18(6): 861.
10. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue. Diabetes, 1997; 46(5): 860